Combined Targeting - Stand Up to Cancer
Help save a life

This holiday season, Mastercard is standing with us in the fight to end cancer as we know it. From now until December 31st, 2018, if you use a Mastercard to donate to Stand Up To Cancer, Mastercard will TRIPLE your gift, up to $300,000!

That’s triple the impact to support groundbreaking cancer research that will help save lives now!

$25 = $75
$50 = $150
$100 = $300
$250 = $750
GIVE FOR LIFE
For every $1 donated through StandUpToCancer.org with a Mastercard, Mastercard will donate $2, up to $300,000. Offer starts 12/14/18 at 12:01am ET and ends 12/31/18 at 11:59pm ET, or at the $300,000 max, whichever comes first.

Research Teams

Research  >  Research Portfolio  >  Dream Teams  >  Combined Targeting

Pancreatic Cancer Collective Research Team:
Combined Targeting of MEK1/MEK2 and Autophagy for Pancreatic Cancer

Grant Term: November 2018–December 2019

The standard of care for people with pancreatic cancer is difficult and often ineffective. To better control this type of cancer, the research team is testing a combination approach that involves shutting down two cellular pathways. The first pathway carries signals that relate to tumor growth, and the second controls a process called autophagy, in which the cell effectively reuses its own interior contents. By shutting down both pathways, the team hopes to slow or stop the growth of pancreatic tumors.

ABOUT THIS TEAM'S RESEARCH

There is no effective, FDA-approved precision therapy for pancreatic cancer (pancreatic ductal adenocarcinoma or PDAC). The standard of care for most PDAC patients remains conventional cytotoxic chemotherapy, which offers high toxicity with little clinical benefit. The Team has discovered that the survival of pancreatic cancer cells relies on two biochemical processes: 1) Intracellular signaling by the RAS pathway; and 2) Autophagic recycling of the cells’ interior contents to generate building blocks for cancer cell metabolism.

Blocking either one of these processes alone has been shown to have negligible effects. But combined blockade of both the RAS pathway (with trametinib, T) and autophagy (with hydroxychloroquine, HCQ), has displayed synergistic antigrowth effects against pancreas cancer cells in vivo. Although both of these FDA-approved drugs have previously been tested in pancreatic cancer patients with little or no effect, they have never been tested in combination.

The team is working toward two goals: 1) elucidating the mechanism(s) by which autophagy is regulated by the RAS pathway, in order to identify predictive biomarkers and new autophagy inhibitors that might be tested in clinical trials; and 2) performing a clinical trial of the T/HCQ combination therapy.

This team is part of the Pancreatic Cancer Collective, an initiative of the Lustgarten Foundation for Pancreatic Cancer Research and Stand Up To Cancer.

MEET THE TEAM

The top scientists and researchers on the Pancreatic Cancer Collective Research Team: Combined Targeting of MEK1/MEK2 and Autophagy for Pancreatic Cancer come from a variety of backgrounds and disciplines, which leads them to great insights upon collaboration. Learn more about the Pancreatic Cancer Collective Research Team: Combined Targeting of MEK1/MEK2 and Autophagy for Pancreatic Cancer.

Team Members

Martin C. McMahon, PhD
University of Utah
Team Leader

Eric Collisson, MD
University of California, San Francisco
Co-leader

Phyllis D. Coley, PhD
University of Utah
Advocate

Thomas A. Kursar, PhD
University of Utah
Advocate

Emily Estheimer
University of Utah
Project Manager

“The long-term, overarching goal of our research is to devise new regimens of combination therapy with reduced toxicity that increase the response rate and survival of pancreatic cancer patients compared to current regimens of chemotherapy.”

Martin C. McMahon, PhD
University of Utah

TEAM PROGRESS UPDATES

Stand Up To Cancer’s research projects are designed to foster collaborative, swift translational research. The hallmarks of these efforts include rigorous application and selection procedures, sufficient funding to allow scientists to focus on the objectives of the grant, and reviews by senior scientists every six months. These reviews help the investigators capitalize on the latest findings, address potential roadblocks, and collaboratively evolve as the science requires. Please click on the link to see summaries of the research results so far for the Combined Targeting of MEK1/MEK2 and Autophagy for Pancreatic Cancer Research Team.

TEAM PROGRESS UPDATES

PUBLICATIONS

This team started its work in November 2018; links to publications will be posted when they are available.

CLINICAL TRIALS REFERRALS

Cancer clinical trials allow researchers to study innovative and potentially life-saving new treatments. The goal is to find treatments that are better than what’s currently available, in fact the therapies offered to today’s cancer patients were almost all studied and made possible by people participating in clinical trials. But many cancer clinical trials don’t get completed because not enough people participate.

At StandUpToCancer.org/ClinicalTrials, you’ll find information and answers to common questions about clinical trials. Learn more and talk to your doctor to see if a clinical trial may be the best choice for you.

You can also connect with EmergingMed, a free and confidential clinical trial matching service that provides access to a vast database to help you identify the clinical trials that might be right for you or your loved one.

LEARN MORE